Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/408
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorGEYS, Helena-
dc.contributor.authorRENARD, Didier-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.contributor.authorALONSO ABAD, Ariel-
dc.date.accessioned2004-10-29T08:59:01Z-
dc.date.available2004-10-29T08:59:01Z-
dc.date.issued2002-
dc.identifier.citationControlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625-
dc.identifier.issn0197-2456-
dc.identifier.urihttp://hdl.handle.net/1942/408-
dc.description.abstractThe validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained. Buyse and Molenberghs proposed to replace the proportion explained by two quantities: (1) the relative effect, linking the effect of treatment on both endpoints, and (2) the adjusted association, an individual-level measure of agreement between both endpoints. In a multiunit setting, these quantities can be generalized to a trial-level measure of surrogacy and an individual-level measure of surrogacy. In this paper, we argue that such a multiunit approach should be adopted because it overcomes difficulties that necessarily surround validation efforts based on a single trial. These difficulties are highlighted.-
dc.description.sponsorshipDr. Geys is supported by a grant from IWT — Vlaanderen. Drs. Burzykowski and Alonso are supported by an LUC Bijzonder Onderzoeksfonds grant.-
dc.language.isoen-
dc.rights(C) 2002 Elsevier Science Inc. All rights reserved.-
dc.subjectClinical trials-
dc.subjectClustered data-
dc.subjectSurrogate Markers-
dc.subject.otheradjusted association; meta-analysis; proportion explained; random-effects model; relative effect; surrogate endpoint; validation-
dc.titleStatistical challenges in the evaluation of surrogate endpoints in randomized trials-
dc.typeJournal Contribution-
dc.identifier.epage625-
dc.identifier.issue6-
dc.identifier.spage607-
dc.identifier.volume23-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
local.bibliographicCitation.artnrPII S0197-2456(02)00236-2-
dc.identifier.doi10.1016/S0197-2456(02)00236-2-
dc.identifier.isi000179835100001-
dc.identifier.urlhttps://www.academia.edu/8393370/Statistical_challenges_in_the_evaluation_of_surrogate_endpoints_in_randomized_trials-
item.fulltextWith Fulltext-
item.contributorMOLENBERGHS, Geert-
item.contributorBUYSE, Marc-
item.contributorGEYS, Helena-
item.contributorRENARD, Didier-
item.contributorBURZYKOWSKI, Tomasz-
item.contributorALONSO ABAD, Ariel-
item.fullcitationMOLENBERGHS, Geert; BUYSE, Marc; GEYS, Helena; RENARD, Didier; BURZYKOWSKI, Tomasz & ALONSO ABAD, Ariel (2002) Statistical challenges in the evaluation of surrogate endpoints in randomized trials. In: Controlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625.-
item.accessRightsOpen Access-
item.validationecoom 2004-
crisitem.journal.issn0197-2456-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0197245602002362-main.pdfPublished version119.35 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.